OraSure Technologies (OSUR) Competitors

$3.25 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.26 +0.00 (+0.15%)

As of 07:41 AM Eastern

OSUR vs. QDEL, CERS, SMTI, EMBC, and RXST

Should you buy OraSure Technologies stock or one of its competitors? OraSure Technologies's main competitors and comparable companies include QuidelOrtho (QDEL), Cerus (CERS), Sanara MedTech (SMTI), Embecta (EMBC), and RxSight (RXST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does OraSure Technologies compare to QuidelOrtho?

OraSure Technologies (NASDAQ:OSUR) and QuidelOrtho (NASDAQ:QDEL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

OraSure Technologies currently has a consensus target price of $3.00, suggesting a potential downside of 7.69%. QuidelOrtho has a consensus target price of $13.63, suggesting a potential upside of 15.66%. Given QuidelOrtho's higher probable upside, analysts plainly believe QuidelOrtho is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

QuidelOrtho has a net margin of -39.20% compared to OraSure Technologies' net margin of -43.70%. QuidelOrtho's return on equity of 4.88% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OraSure Technologies	-43.70%	-19.09%	-16.26%
QuidelOrtho	-39.20%	4.88%	1.63%

93.5% of OraSure Technologies shares are held by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are held by institutional investors. 4.7% of OraSure Technologies shares are held by insiders. Comparatively, 1.1% of QuidelOrtho shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

OraSure Technologies has higher earnings, but lower revenue than QuidelOrtho. OraSure Technologies is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OraSure Technologies	$115.02M	1.95	-$68.73M	-$0.69	N/A
QuidelOrtho	$2.73B	0.30	-$1.13B	-$15.41	N/A

OraSure Technologies has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

In the previous week, QuidelOrtho had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 2 mentions for QuidelOrtho and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 1.61 beat QuidelOrtho's score of 1.23 indicating that OraSure Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
OraSure Technologies	Very Positive
QuidelOrtho	Positive

Summary

QuidelOrtho beats OraSure Technologies on 8 of the 14 factors compared between the two stocks.

How does OraSure Technologies compare to Cerus?

Cerus (NASDAQ:CERS) and OraSure Technologies (NASDAQ:OSUR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

In the previous week, Cerus had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 2 mentions for Cerus and 1 mentions for OraSure Technologies. Cerus' average media sentiment score of 1.77 beat OraSure Technologies' score of 1.61 indicating that Cerus is being referred to more favorably in the media.

Company	Overall Sentiment
Cerus	Very Positive
OraSure Technologies	Very Positive

Cerus presently has a consensus target price of $5.25, suggesting a potential upside of 110.84%. OraSure Technologies has a consensus target price of $3.00, suggesting a potential downside of 7.69%. Given Cerus' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cerus is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Cerus has a net margin of -3.06% compared to OraSure Technologies' net margin of -43.70%. Cerus' return on equity of -10.19% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
OraSure Technologies	-43.70%	-19.09%	-16.26%

Cerus has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, OraSure Technologies has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

Cerus has higher revenue and earnings than OraSure Technologies. Cerus is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.43	-$15.63M	-$0.03	N/A
OraSure Technologies	$115.02M	1.95	-$68.73M	-$0.69	N/A

78.4% of Cerus shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 5.3% of Cerus shares are held by insiders. Comparatively, 4.7% of OraSure Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cerus beats OraSure Technologies on 14 of the 16 factors compared between the two stocks.

How does OraSure Technologies compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and OraSure Technologies (NASDAQ:OSUR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Sanara MedTech had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 2 mentions for Sanara MedTech and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 1.61 beat Sanara MedTech's score of 0.92 indicating that OraSure Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Sanara MedTech	Positive
OraSure Technologies	Very Positive

Sanara MedTech has higher earnings, but lower revenue than OraSure Technologies. Sanara MedTech is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.11	-$37.56M	-$3.59	N/A
OraSure Technologies	$115.02M	1.95	-$68.73M	-$0.69	N/A

Sanara MedTech currently has a consensus target price of $35.00, suggesting a potential upside of 0.23%. OraSure Technologies has a consensus target price of $3.00, suggesting a potential downside of 7.69%. Given Sanara MedTech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Sanara MedTech is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Sanara MedTech has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, OraSure Technologies has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

Sanara MedTech has a net margin of -29.15% compared to OraSure Technologies' net margin of -43.70%. Sanara MedTech's return on equity of 29.72% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
OraSure Technologies	-43.70%	-19.09%	-16.26%

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by company insiders. Comparatively, 4.7% of OraSure Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Sanara MedTech beats OraSure Technologies on 10 of the 15 factors compared between the two stocks.

How does OraSure Technologies compare to Embecta?

OraSure Technologies (NASDAQ:OSUR) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

93.5% of OraSure Technologies shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 4.7% of OraSure Technologies shares are held by insiders. Comparatively, 1.3% of Embecta shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Embecta has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OraSure Technologies	$115.02M	1.95	-$68.73M	-$0.69	N/A
Embecta	$1.08B	0.26	$95.40M	$1.48	3.34

OraSure Technologies presently has a consensus price target of $3.00, suggesting a potential downside of 7.69%. Embecta has a consensus price target of $11.00, suggesting a potential upside of 122.67%. Given Embecta's stronger consensus rating and higher probable upside, analysts plainly believe Embecta is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

OraSure Technologies has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Embecta has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

In the previous week, Embecta had 4 more articles in the media than OraSure Technologies. MarketBeat recorded 5 mentions for Embecta and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 1.61 beat Embecta's score of 1.28 indicating that OraSure Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
OraSure Technologies	Very Positive
Embecta	Positive

Embecta has a net margin of 8.59% compared to OraSure Technologies' net margin of -43.70%. OraSure Technologies' return on equity of -19.09% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OraSure Technologies	-43.70%	-19.09%	-16.26%
Embecta	8.59%	-19.25%	10.82%

Summary

Embecta beats OraSure Technologies on 10 of the 15 factors compared between the two stocks.

How does OraSure Technologies compare to RxSight?

RxSight (NASDAQ:RXST) and OraSure Technologies (NASDAQ:OSUR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

78.8% of RxSight shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Comparatively, 4.7% of OraSure Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

RxSight has a net margin of -36.80% compared to OraSure Technologies' net margin of -43.70%. RxSight's return on equity of -17.35% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
OraSure Technologies	-43.70%	-19.09%	-16.26%

RxSight currently has a consensus target price of $8.37, indicating a potential upside of 38.98%. OraSure Technologies has a consensus target price of $3.00, indicating a potential downside of 7.69%. Given RxSight's stronger consensus rating and higher probable upside, equities research analysts plainly believe RxSight is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.91
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

RxSight has higher revenue and earnings than OraSure Technologies. RxSight is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.86	-$38.94M	-$1.13	N/A
OraSure Technologies	$115.02M	1.95	-$68.73M	-$0.69	N/A

RxSight has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, OraSure Technologies has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

In the previous week, RxSight had 4 more articles in the media than OraSure Technologies. MarketBeat recorded 5 mentions for RxSight and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 1.61 beat RxSight's score of 0.66 indicating that OraSure Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
RxSight	Positive
OraSure Technologies	Very Positive

Summary

RxSight beats OraSure Technologies on 11 of the 16 factors compared between the two stocks.

Get OraSure Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OSUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OSUR vs. The Competition

Export

Metric	OraSure Technologies	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$224.15M	$5.40B	$7.15B	$12.84B
Dividend Yield	N/A	1.80%	2.57%	11.71%
P/E Ratio	-4.71	25.09	275.24	25.35
Price / Sales	1.95	71.56	647.32	90.72
Price / Cash	N/A	33.03	28.42	34.96
Price / Book	0.68	5.97	10.33	6.21
Net Income	-$68.73M	$150.75M	$3.50B	$358.54M
7 Day Performance	-6.61%	-2.76%	-3.32%	-2.39%
1 Month Performance	-15.36%	-3.37%	-0.87%	-3.39%
1 Year Performance	-1.81%	9.43%	23.52%	8.81%

OraSure Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OSUR OraSure Technologies	0.9882 of 5 stars	$3.25 flat	$3.00 -7.7%	-1.8%	$224.15M	$115.02M	N/A	840	Positive News
QDEL QuidelOrtho	2.9565 of 5 stars	$13.26 -5.1%	$13.63 +2.8%	-58.8%	$908.55M	$2.73B	N/A	6,500	Positive News
CERS Cerus	1.9706 of 5 stars	$2.57 -1.0%	$5.25 +104.7%	+102.4%	$516.90M	$206.13M	N/A	290	Positive News
SMTI Sanara MedTech	0.6504 of 5 stars	$34.95 +0.6%	$35.00 +0.1%	+2.8%	$321.18M	$103.12M	N/A	60
EMBC Embecta	3.6574 of 5 stars	$5.63 -3.0%	$11.00 +95.6%	-67.1%	$318.54M	$1.08B	3.80	1,850	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OSUR) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OraSure Technologies (OSUR) Competitors

OSUR vs. QDEL, CERS, SMTI, EMBC, and RXST

How does OraSure Technologies compare to QuidelOrtho?

Summary

How does OraSure Technologies compare to Cerus?

Summary

How does OraSure Technologies compare to Sanara MedTech?

Summary

How does OraSure Technologies compare to Embecta?

Summary

How does OraSure Technologies compare to RxSight?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSUR vs. The Competition

OraSure Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OraSure Technologies (OSUR) Competitors

OSUR vs. QDEL, CERS, SMTI, EMBC, and RXST

How does OraSure Technologies compare to QuidelOrtho?

Do analysts rate OSUR or QDEL?

Is OSUR or QDEL more profitable?

Do insiders & institutionals hold more shares of OSUR or QDEL?

Which has better earnings and valuation, OSUR or QDEL?

Which has more volatility & risk, OSUR or QDEL?

Does the media refer more to OSUR or QDEL?

Summary

How does OraSure Technologies compare to Cerus?

Does the media refer more to CERS or OSUR?

Do analysts prefer CERS or OSUR?

Is CERS or OSUR more profitable?

Which has more risk and volatility, CERS or OSUR?

Which has preferable earnings and valuation, CERS or OSUR?

Do institutionals & insiders hold more shares of CERS or OSUR?

Summary

How does OraSure Technologies compare to Sanara MedTech?

Does the media favor SMTI or OSUR?

Which has preferable valuation & earnings, SMTI or OSUR?

Do analysts rate SMTI or OSUR?

Which has more volatility & risk, SMTI or OSUR?

Is SMTI or OSUR more profitable?

Do institutionals and insiders hold more shares of SMTI or OSUR?

Summary

How does OraSure Technologies compare to Embecta?

Do insiders and institutionals hold more shares of OSUR or EMBC?

Which has stronger valuation & earnings, OSUR or EMBC?

Do analysts recommend OSUR or EMBC?

Which has more risk and volatility, OSUR or EMBC?

Does the media favor OSUR or EMBC?

Is OSUR or EMBC more profitable?

Summary

How does OraSure Technologies compare to RxSight?

Do insiders and institutionals believe in RXST or OSUR?

Is RXST or OSUR more profitable?

Do analysts rate RXST or OSUR?

Which has higher valuation and earnings, RXST or OSUR?

Which has more volatility and risk, RXST or OSUR?

Does the media favor RXST or OSUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSUR vs. The Competition

OraSure Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools